T S K Mok
Overview
Explore the profile of T S K Mok including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
608
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mok T, Lopes G, Cho B, Kowalski D, Kasahara K, Wu Y, et al.
Ann Oncol
. 2023 Jan;
34(4):377-388.
PMID: 36709038
Background: We evaluated whether tissue tumor mutational burden (tTMB) and STK11, KEAP1, and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with programmed...
2.
Passaro A, Peters S, Mok T, Attili I, Mitsudomi T, de Marinis F
Ann Oncol
. 2020 Apr;
31(7):832-834.
PMID: 32278879
No abstract available.
3.
Lin G, Li C, Li P, Fang W, Xu H, Gong Y, et al.
Ann Oncol
. 2020 Mar;
31(4):517-524.
PMID: 32151507
Background: Adenosquamous carcinoma (ASC) of the lung is a heterogeneous disease that is composed of both adenocarcinoma components (ACC) and squamous cell carcinoma components (SCCC). Their genomic profile, genetic origin,...
4.
Lee V, Mok T, Goto Y, Hsue V, Yang L, Jiang Y, et al.
Clin Oncol (R Coll Radiol)
. 2019 Aug;
32(1):e1-e9.
PMID: 31375307
Lung cancer is a common cancer associated with high mortality rates worldwide. Unfortunately, it usually presents at a late stage, precluding the chance of curative therapy. The discovery of oncogenic...
5.
Molassiotis A, Suen L, Cheng H, Mok T, Lee S, Wang C, et al.
Integr Cancer Ther
. 2019 Mar;
18:1534735419836501.
PMID: 30905173
Purpose: Chemotherapy-induced peripheral neuropathy is a complex side effect with few available treatment options. The aim of the study was to test the effectiveness of an 8-week course of acupuncture...
6.
Nokihara H, Lu S, Mok T, Nakagawa K, Yamamoto N, Shi Y, et al.
Ann Oncol
. 2017 Oct;
28(11):2698-2706.
PMID: 29045553
Background: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral...
7.
Chan O, Lee V, Mok T, Mo F, Chang A, Yeung R
Clin Oncol (R Coll Radiol)
. 2017 May;
29(9):568-575.
PMID: 28499791
Aims: Almost all patients with epidermal growth factor receptor (EGFR) mutations will develop resistance to first-line EGFR tyrosine kinase inhibitors (TKIs). The management of oligoprogression on EGFR TKI is controversial....
8.
Blumenschein Jr G, Kabbinavar F, Menon H, Mok T, Stephenson J, Beck J, et al.
Ann Oncol
. 2011 Feb;
22(9):2057-2067.
PMID: 21321086
Background: This phase II study estimated the difference in objective response rate (ORR) among patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) receiving paclitaxel-carboplatin (CP) plus motesanib or bevacizumab. Patients...
9.
Lui V, Wong E, Ho K, Ng P, Lau C, Tsui S, et al.
Oncogene
. 2010 Nov;
30(9):1127-34.
PMID: 21057531
c-Met represents an important emerging therapeutic target in cancer. In this study, we demonstrate the mechanism by which c-Met tyrosine kinase inhibition inhibits tumor growth in a highly invasive Asian-prevalent...
10.
Huang R, Li M, Hsin M, Underwood M, Ma L, Mok T, et al.
Oncogene
. 2010 Sep;
30(1):106-16.
PMID: 20818420
The role of thromboxane A(2) (TxA(2)) in smoking-associated lung cancer is poorly understood. This study was conducted to study the role of TxA(2) in smoking carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-promoted cell survival...